177 related articles for article (PubMed ID: 27165496)
21. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
Bays AM; Gardner G
Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
[TBL] [Abstract][Full Text] [Related]
22. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
Jani M; Dixon WG; Chinoy H
Rheumatology (Oxford); 2018 Nov; 57(11):1896-1907. PubMed ID: 29325166
[TBL] [Abstract][Full Text] [Related]
23. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2014 Dec; 56(1458):127-32. PubMed ID: 25519024
[No Abstract] [Full Text] [Related]
24. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.
Ozguler Y; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Borekci S; Atahan E; Ongen G; Hamuryudan V
Rheumatol Int; 2016 Dec; 36(12):1719-1725. PubMed ID: 27699578
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
[TBL] [Abstract][Full Text] [Related]
26. Biologic therapies and pregnancy: the story so far.
Hyrich KL; Verstappen SM
Rheumatology (Oxford); 2014 Aug; 53(8):1377-85. PubMed ID: 24352337
[TBL] [Abstract][Full Text] [Related]
27. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
[TBL] [Abstract][Full Text] [Related]
28. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
29. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.
Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordström D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32900882
[No Abstract] [Full Text] [Related]
30. Rheumatoid vasculitis in 2023: Changes and challenges since the biologics era.
Mertz P; Wollenschlaeger C; Chasset F; Dima A; Arnaud L
Autoimmun Rev; 2023 Sep; 22(9):103391. PubMed ID: 37468085
[TBL] [Abstract][Full Text] [Related]
31. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan.
Nakajima A; Saito K; Kojima T; Amano K; Yoshio T; Fukuda W; Inoue E; Taniguchi A; Momohara S; Minota S; Takeuchi T; Ishiguro N; Tanaka Y; Yamanaka H
Mod Rheumatol; 2013 Sep; 23(5):945-52. PubMed ID: 23073692
[TBL] [Abstract][Full Text] [Related]
32. [The proposal of the Croatian Society for Rheumatology for the treatment of adult rheumatoid arthritis patients with biologics, 2013].
Babić-Naglić D; Anić B; Čikeš N; Novak S; Grazio S; Morović-Vergles J; Kehler T; Marasović-Krstulović D; Milanović S; Hanih M; Perić P; Vlak T; Potokič K; Ćurković B;
Reumatizam; 2013; 60(1):47-51. PubMed ID: 24003685
[TBL] [Abstract][Full Text] [Related]
33. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
34. Rheumatoid arthritis.
Lorenzo M
Foot Ankle Clin; 2007 Sep; 12(3):525-37, vii. PubMed ID: 17765843
[TBL] [Abstract][Full Text] [Related]
35. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
Tanaka Y; Hirata S
Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
[TBL] [Abstract][Full Text] [Related]
36. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
37. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation.
Ngian GS; Briggs AM; Ackerman IN; Van Doornum S
Int J Rheum Dis; 2016 Sep; 19(9):834-43. PubMed ID: 27125255
[TBL] [Abstract][Full Text] [Related]
38. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
[TBL] [Abstract][Full Text] [Related]
39. Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.
Jagpal A; Curtis JR
Drug Saf; 2018 Jun; 41(6):545-553. PubMed ID: 29392593
[TBL] [Abstract][Full Text] [Related]
40. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y; Shi N; John A
Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
